These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34237811)

  • 1. Clinical utilization of four-factor prothrombin complex concentrate: a retrospective single center study.
    Naeem Z; Allan S; Hernandez A; Galanakis DK; Singer AJ
    Clin Exp Emerg Med; 2021 Jun; 8(2):75-81. PubMed ID: 34237811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.
    Maguire M; Fuh L; Goldstein JN; Marshall AL; Levine M; Howell ML; Parry BA; Rosovsky R; Hayes BD
    West J Emerg Med; 2019 Jul; 20(4):619-625. PubMed ID: 31316701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-label compared to off-label four-factor prothrombin complex concentrate use: a retrospective, observational study.
    Cho BC; Jung YH; DeMario VM; Lau E; Podlasek SJ; Grant MC; Gehrie EA; Frank SM
    Transfusion; 2019 Aug; 59(8):2678-2684. PubMed ID: 31121073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-factor prothrombin complex concentrate use for on-label versus off-label indications: a retrospective cohort study.
    Adkins BD; Shaim H; Abid A; Gonzalez A; DeAnda A; Yates SG
    J Thromb Thrombolysis; 2023 Jan; 55(1):74-82. PubMed ID: 35699871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.
    Rimsans J; Levesque A; Lyons E; Sylvester K; Givertz MM; Mehra MR; Stewart GC; Connors JM
    J Thromb Thrombolysis; 2018 Aug; 46(2):180-185. PubMed ID: 29785470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
    Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
    Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding.
    Tanaka KA; Shettar S; Vandyck K; Shea SM; Abuelkasem E
    Transfus Med Rev; 2021 Oct; 35(4):96-103. PubMed ID: 34551881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of four-factor prothrombin complex concentrate (4F-PCC) for management of bleeding not associated with therapeutic anticoagulant use.
    Uttaro E; Young MR; Falvey J; Corvelli JM; Acquisto NM
    Transfus Apher Sci; 2023 Oct; 62(5):103759. PubMed ID: 37453907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization and safety of off-label prothrombin complex concentrate (four-factor prothrombin complex concentrate) in a surgical population.
    Sandquist K; Kaucher K; Newell J; Sarangarm P; Burnett A
    Blood Coagul Fibrinolysis; 2024 Apr; 35(3):124-128. PubMed ID: 38477833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
    Kuroski JE; Young S
    Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding.
    Holt T; Taylor S; Abraham P; Mcmillian W; Harris S; Curtis J; Elder T
    Int J Crit Illn Inj Sci; 2018; 8(1):36-40. PubMed ID: 29619338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new kid on the block: Outcomes with Kcentra 1 year after approval.
    Berndtson AE; Huang WT; Box K; Kobayashi L; Godat LN; Smith AM; Weingarten D; Coimbra R
    J Trauma Acute Care Surg; 2015 Dec; 79(6):1004-8. PubMed ID: 26488322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study.
    Dodhiawala PB; Pribyl K; Larson J; Vakayil V; Chandrashekar M; Lord A; Welbig J; Zantek ND; Martin D; Harmon JV
    Clin Appl Thromb Hemost; 2023; 29():10760296231198038. PubMed ID: 37649304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding.
    Go AS; Leong TK; Sung SH; Wei R; Harrison TN; Gupta N; Baker N; Goldstein B; Ataher Q; Solomon MD; Reynolds K;
    J Thromb Thrombolysis; 2022 Oct; 54(3):470-479. PubMed ID: 35984591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal.
    Makhoul T; Kelly G; Kersten B; Nadler M; Zammit CG; Jones CMC; Scott R; Acquisto NM
    Thromb Res; 2020 Oct; 194():158-164. PubMed ID: 32788109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
    Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
    J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.